Serum Proteome Profile of Crohn's Disease Patients Treated With infliximab: A Pilot Study

被引：0
|
作者：
Gazouli, Maria
Mantzaris, Gerassimos J.
Papamichael, Konstantinos
Papadopoulou, Aggeliki
Vougas, Konstantinos
Anagnou, Nicholas P.
Tsangaris, George T.
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S274 / S275
页数：2
相关论文
共 50 条
  • [21] Crohn's disease arthritis treated with infliximab: An open trial in four patients
    Ellman, MH
    Hanauer, S
    Sitrin, M
    Cohen, R
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2001, 7 (02) : 67 - 71
  • [22] Opportunistic infections in patients treated with infliximab for Crohn's disease and rheumatoid arthritis
    Gershon, SK
    Slifman, NR
    Braun, MM
    GASTROENTEROLOGY, 2002, 122 (04) : A470 - A470
  • [23] Infliximab treatment decreases serum osteoprotegerin concentration in patients with Crohn's disease
    Miheller, Pal
    Muzes, Gyorgyi
    Racz, Karoly
    Blazovits, Anna
    Lakatos, Peter
    Herszenyi, Laszlo
    Tulassay, Zsolt
    GASTROENTEROLOGY, 2007, 132 (04) : A364 - A364
  • [24] Cytokine production profile in patients with Behcet's disease treated with infliximab
    Misumi, M
    Hagiwara, E
    Takeno, M
    Takeda, Y
    Inoue, Y
    Tsuji, T
    Ueda, A
    Nakamura, S
    Ohn, S
    Ishigatsubo, Y
    CYTOKINE, 2003, 24 (05) : 210 - 218
  • [25] DIFFERENCE IN CLINICAL EFFICACY AND SAFETY PROFILE IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB ACCORDING TO TIMING FOR ADDITION OF THIOPURINE
    Zeze, Keizo
    Hirano, Atsushi
    Torisu, Takehiro
    Esaki, Motohiro
    Kitazono, Takanari
    GASTROENTEROLOGY, 2019, 156 (03) : S39 - S39
  • [26] DIFFERENCE IN CLINICAL EFFICACY AND SAFETY PROFILE IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB ACCORDING TO TIMING FOR ADDITION OF THIOPURINE
    Zeze, Keizo
    Hirano, Atsushi
    Torisu, Takehiro
    Esaki, Motohiro
    Kitazono, Takanari
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S27 - S27
  • [27] Desensitisation to infliximab in patients with Crohn's disease
    Lelong, J
    Duburque, C
    Fournier, C
    Colombel, JF
    Desreumaux, P
    Tonnel, AB
    Wallaert, B
    REVUE DES MALADIES RESPIRATOIRES, 2005, 22 (02) : 239 - 246
  • [28] The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
    Colombel, JF
    Loftus, EV
    Tremaine, WJ
    Egan, LJ
    Harmsen, WS
    Schleck, CD
    Zinsmeister, AR
    Sandborn, WJ
    GASTROENTEROLOGY, 2004, 126 (01) : 19 - 31
  • [29] Treatment of Secondary Infliximab Failure in Crohn's Disease Based on Serum Levels of Infliximab and Antibodies Against Infliximab: The Danish Study of Optimizing Infliximab Therapy in Crohn's Disease (Do It Crohn) Randomized Clinical Trial
    Steenholdt, Casper
    Brynskov, Jorn
    Thomsen, Ole
    Munck, Lars K.
    Fallingborg, Jan
    Christensen, Lisbet A.
    Pedersen, Gitte
    Kjeldsen, Jens
    Jacobsen, Bent A.
    Oxholm, Anne Sophie
    Kjellberg, Jakob
    Bendtzen, Klaus
    Ainsworth, Mark A.
    GASTROENTEROLOGY, 2013, 144 (05) : S22 - S22
  • [30] THE CLINICAL UTILITY OF A MULTI-MARKER SERUM TEST FOR ASSESSMENT OF ULCERATIONS IN INFLIXIMAB TREATED PATIENTS WITH CROHN'S DISEASE
    de Bruyn, Magali
    Bessissow, Talat
    Kondragunta, Venkateswarlu
    Jain, Anjali
    Arijs, Ingrid
    Van Assche, Gert A.
    Ferrante, Marc
    Opdenakker, Ghislain
    Vermeire, Severine
    GASTROENTEROLOGY, 2018, 154 (06) : S597 - S597
12345